EuroPCR 2025 | Individual Patient Data Meta-analysis of PROTECTED TAVR and BHF PROTECT-TAVI

Stroke remains a significant complication associated with the various transcatheter aortic valve implantation (TAVI) devices currently in use. The Sentinel cerebral embolic protection (CEP) device could capture embolic debris during TAVI procedures; however, randomized trials have so far failed to show a significant reduction in stroke incidence.

Two major studies were conducted: PROTECTED TAVR (3,000 patients, primarily from the U.S.) and BHF PROTECT-TAVI (7,635 patients from the U.K.), both evaluating stroke occurrence within 72 hours post-TAVI or at hospital discharge. In both trials, a non-significant reduction in neurovascular events was observed (-0.6%, p=0.30 and -0.02%, p=0.94, respectively).

Based on these data, researchers carried out a meta-analysis of individual patient data. A primary analysis assessed stroke incidence (within 72 hours or at discharge) between patients who received CEP and those who did not. A per-protocol analysis was also conducted, including only patients with both CEP filters correctly deployed.

Upon primary analysis, stroke incidence did not show significant differences. However, upon per-protocol analysis, the CEP group showed a lower stroke rate (2.3% vs. 1.7%; P=0.023), though not sustained after adjusting for confounding factors.

Read also: EuroPCR 2025 | Angiography- vs. Physiology-Guided PCI in TAVI Candidates (FAITAVI).

Regarding disabling stroke, the subgroup with proper positioning of both filters showed significantly lower incidence (1.3% vs. 0.8%; P=0.007) at per-protocol analysis.

The authors concluded that there is insufficient evidence to support the routine use of CEP to reduce stroke incidence. They emphasized the need to further identify high-risk subgroups that may benefit from this strategy.

Presented by R. Kharbanda during the Major Late Breaking Trials session, EuroPCR 2025, May 21, Paris, France.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Omar Tupayachi
Dr. Omar Tupayachi
Member of the Editorial Board of solaci.org

More articles by this author

Transapical TMVR in High Risk Patients: Intrepid 5-Year Outcomes

Moderate to severe mitral valve regurgitation (MR) continues is still a high prevalence condition with bad prognosis, particularly among the elderly with left ventricular...

Impact of Balloon Post-Dilation on the Long-Term Durability of Bioprostheses after TAVR

Balloon post-dilation (BPD) during transcatheter aortic valve replacement (TAVR) allows for the optimization of prosthesis expansion and the reduction of residual paravalvular aortic regurgitation....

TAVR in Pure Native Aortic Regurgitation: Are Dedicated Devices Truly Superior?

This systematic meta-analysis assessed the efficacy and safety of transcatheter aortic valve replacement (TAVR) in patients with pure native aortic regurgitation. The emergence of...

Contemporary Challenges in Left Atrial Appendage Closure: Updated Approach to Device Embolization

Even though percutaneous left atrial appendage (LAA) closure is generally safe, device embolization – with 0 to 1.5% global incidence – is still a...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Transapical TMVR in High Risk Patients: Intrepid 5-Year Outcomes

Moderate to severe mitral valve regurgitation (MR) continues is still a high prevalence condition with bad prognosis, particularly among the elderly with left ventricular...

EMERALD II: Non-Invasive Coronary Anatomy and Physiology (CCTA) in ACS Prediction

Despite steady progress in secondary prevention and medical treatment optimization (OMT), acute coronary syndrome (ACS) remains one of the leading causes of cardiovascular morbimortality....

Impact of Balloon Post-Dilation on the Long-Term Durability of Bioprostheses after TAVR

Balloon post-dilation (BPD) during transcatheter aortic valve replacement (TAVR) allows for the optimization of prosthesis expansion and the reduction of residual paravalvular aortic regurgitation....